Hematopoietic Stem Cell Transplantation

清髓性方案涉及高剂量TBI损害心脏功能。HCT前高水平的s-铁蛋白可能与HCT慢性期LVH的发生有关。HCT后高的s-铁蛋白水平可能是一个预后因素。allo-HCT后嗜酸性粒细胞增多与更好的OS和更低的复发率相关。Th1/Th2细胞因子失衡可能在allo-HCT后HPS的发生中起重要作用。对预后不良或难治性白血病和MDS患者进行移植后使用环磷酰胺的HLA半相合异基因PBSCT的前瞻性初步研究显示，除1例患者因疾病进展死亡外，所有患者在第30天均达到完全供体T细胞嵌合，53%的患者发生II-III级急性GVHD，1年TRM累积发生率为13%，全组、缓解组和活动组的1年OS分别为43%、75%和31%。

A myeloablative regimen involved high-dose TBI impaired cardiac function. A high s-ferritin level before HCT might be associated with the development of LVH in the chronic phase of HCT. A high s-ferritin level after HCT might be a prognostic factor. Eosinophilia after allo-HCT was associated with better OS and a lower relapse rate. Dysregulated balance between Th1 and Th2 cytokines might play an important role in the incidence of HPS after allo-HCT. Prospective pilot study of HLA haplo-identical allogeneic PBSCT using cyclophosphamide post-transplantation for patients with a poor-prognosis or refractory leukemia and MDS showed that except for one patient who died due to disease progression, full donor T-cell chimerism was achieved at day 30 in all patients, 53% of patients developed grade II-III acute GVHD, the cumulative incidence of TRM at one year was 13%, and the OS at one year of all patients, patients in remission and those with active disease were 43%, 75% and 31%, respectively.